These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 7490907

  • 1. Up-front intravesical chemotherapy for low stage, low grade recurrent bladder cancer.
    Maffezzini M, Simonato A, Zanon M, Raber M, Carmignani G.
    J Urol; 1996 Jan; 155(1):91-3. PubMed ID: 7490907
    [Abstract] [Full Text] [Related]

  • 2. Combined local bladder hyperthermia and intravesical chemotherapy for the treatment of high-grade superficial bladder cancer.
    Gofrit ON, Shapiro A, Pode D, Sidi A, Nativ O, Leib Z, Witjes JA, van der Heijden AG, Naspro R, Colombo R.
    Urology; 2004 Mar; 63(3):466-71. PubMed ID: 15028439
    [Abstract] [Full Text] [Related]

  • 3. The effect of repeat transurethral resection on recurrence and progression rates in patients with T1 tumors of the bladder who received intravesical mitomycin: a prospective, randomized clinical trial.
    Divrik RT, Yildirim U, Zorlu F, Ozen H.
    J Urol; 2006 May; 175(5):1641-4. PubMed ID: 16600720
    [Abstract] [Full Text] [Related]

  • 4. Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations.
    Lebret T, Bohin D, Kassardjian Z, Herve JM, Molinie V, Barre P, Lugagne PM, Botto H.
    J Urol; 2000 Jan; 163(1):63-7. PubMed ID: 10604315
    [Abstract] [Full Text] [Related]

  • 5. [Short-term versus long-term chemoprevention of recurrence with Epodyl following transurethral resection of superficial urinary bladder cancer].
    Flamm J, Kühnel W, Dona S.
    Urologe A; 1989 Mar; 28(2):99-102. PubMed ID: 2655259
    [Abstract] [Full Text] [Related]

  • 6. TUR and adjuvant intravesical chemotherapy in T1G3 bladder tumors: recurrence, progression and survival in 137 selected patients followed up to 20 years.
    Serretta V, Pavone C, Ingargiola GB, Daricello G, Allegro R, Pavone-Macaluso M.
    Eur Urol; 2004 Jun; 45(6):730-5; discussion 735-6. PubMed ID: 15149744
    [Abstract] [Full Text] [Related]

  • 7. [Long-term results of intravesical prevention of recurrence with mitomycin C and adriamycin in patients with superficial bladder cancer].
    Schwaibold H, Klingenberger HJ, Huland H.
    Urologe A; 1994 Nov; 33(6):479-83. PubMed ID: 7817443
    [Abstract] [Full Text] [Related]

  • 8. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for select multifocal and unresectable superficial bladder tumors.
    Colombo R, Da Pozzo LF, Lev A, Salonia A, Rigatti P, Leib Z, Servadio C, Caldarera E, Pavone-Macaluso M.
    J Urol; 1998 Mar; 159(3):783-7. PubMed ID: 9474148
    [Abstract] [Full Text] [Related]

  • 9. The expression of p53 and bcl-2 in superficial bladder transitional cell carcinoma and its role in the outcome of postoperative intravesical chemotherapy.
    Tzai TS, Chow NH, Lin JS, Yang WH, Tong YC.
    Anticancer Res; 1998 Mar; 18(6B):4717-21. PubMed ID: 9891547
    [Abstract] [Full Text] [Related]

  • 10. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
    Huncharek M, McGarry R, Kupelnick B.
    Anticancer Res; 2001 Mar; 21(1B):765-9. PubMed ID: 11299841
    [Abstract] [Full Text] [Related]

  • 11. Adjuvant intravesical mitoxantrone versus recombinant interferon-alpha after transurethral resection of superficial bladder cancer: a randomized prospective study.
    Papatsoris AG, Deliveliotis C, Giannopoulos A, Dimopoulos C.
    Urol Int; 2004 Mar; 72(4):284-91. PubMed ID: 15153724
    [Abstract] [Full Text] [Related]

  • 12. Proton beam therapy for invasive bladder cancer: a prospective study of bladder-preserving therapy with combined radiotherapy and intra-arterial chemotherapy.
    Hata M, Miyanaga N, Tokuuye K, Saida Y, Ohara K, Sugahara S, Kagei K, Igaki H, Hashimoto T, Hattori K, Shimazui T, Akaza H, Akine Y.
    Int J Radiat Oncol Biol Phys; 2006 Apr 01; 64(5):1371-9. PubMed ID: 16580495
    [Abstract] [Full Text] [Related]

  • 13. Update on the Dutch Cooperative Trial: mitomycin versus bacillus Calmette-Guérin-Tice versus bacillus Calmette-Guérin RIVM in the treatment of patients with pTA-pT1 papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.
    Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ.
    Semin Urol Oncol; 1996 Feb 01; 14(1 Suppl 1):10-6. PubMed ID: 8727805
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
    Stavropoulos NE, Filiadis I, Ioachim E, Hastazeris K, Tsimaris I, Kalogeras D, Stefanaki S, Agnantis NJ.
    Anticancer Res; 2002 Feb 01; 22(6B):3759-64. PubMed ID: 12552989
    [Abstract] [Full Text] [Related]

  • 17. [Instillation chemotherapy with peplomycin in superficial bladder cancer: clinical study on the effects of the direct antitumor activity and of the prophylaxis of recurrence].
    Sonoda T, Osafune M, Matsuda M, Usami M.
    Hinyokika Kiyo; 1988 Mar 01; 34(3):574-81. PubMed ID: 2455442
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup.
    Solsona E, Iborra I, Ricós JV, Monrós JL, Casanova J, Dumont R.
    J Urol; 1999 Apr 01; 161(4):1120-3. PubMed ID: 10081851
    [Abstract] [Full Text] [Related]

  • 19. [Initial conservative treatment for grade 3 Ta-1 superficial bladder cancer].
    Fujimoto K, Chihara Y, Kondo H, Hirao Y.
    Hinyokika Kiyo; 2006 Jun 01; 52(6):433-8. PubMed ID: 16848356
    [Abstract] [Full Text] [Related]

  • 20. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug 01; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.